Tim Tasker
Chief Tech/Sci/R&D Officer presso Heptares Therapeutics Ltd.
Provenienza dei contatti di primo grado di Tim Tasker
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Tim Tasker tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Imperial College London | College/University | Doctorate Degree | |
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
University of Cambridge | College/University | Doctorate Degree | |
Cambridge Drug Discovery Holdings Ltd.
Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a private company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Miscellaneous Commercial Services | Founder | |
Biological Sciences Research Council
Biological Sciences Research Council Investment Banks/BrokersFinance The Biological Sciences Research Council operates as a funding agency for academic research and training in the biosciences arena. The private company is based in Swindon, UK and has subsidiaries in United Kingdom. | Investment Banks/Brokers | Corporate Officer/Principal | |
Monash University
Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Undergraduate Degree | |
Sosei R&D Ltd.
Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
University of Leicester | College/University | Undergraduate Degree | |
Lifearc
Lifearc Miscellaneous Commercial ServicesCommercial Services Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
NXERA PHARMA CO., LTD. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Executive Officer | |
Takeda Cambridge Ltd.
Takeda Cambridge Ltd. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda Cambridge Ltd. is a private company that develops and manufactures pharmaceutical products. The company is based in Cambridge, UK and was founded in 1998. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pfizer Central Research | Corporate Officer/Principal | ||
The Biochemical Society
The Biochemical Society Miscellaneous Commercial ServicesCommercial Services The Biochemical Society conducts research in various areas of molecular biosciences, including biological clocks, gene therapy, embryogenesis, and more. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The British company also provides public engagement and outreach resources and offer grants, prizes, and support to science communicators. | Miscellaneous Commercial Services | Director/Board Member | |
Biofocus, Inc.
Biofocus, Inc. Pharmaceuticals: MajorHealth Technology Biofocus, Inc. operates as a clinical biotechnology company. The company is headquartered in the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Biotechnology | Director/Board Member | |
Heptares Therapeutics Zurich AG
Heptares Therapeutics Zurich AG Pharmaceuticals: MajorHealth Technology Part of Nxera Pharma Co., Ltd., Heptares Therapeutics Zurich AG is a private company that provides drug discovery and development services. Heptares Therapeutics Zurich AG is based in Zurich, Switzerland. | Pharmaceuticals: Major | Chairman |
Statistiche
Distribuzione geografica
Regno Unito | 18 |
Australia | 2 |
Giappone | 2 |
Stati Uniti | 2 |
Svizzera | 2 |
Settori
Health Technology | 13 |
Consumer Services | 5 |
Commercial Services | 4 |
Finance | 2 |
Posizioni
Corporate Officer/Principal | 16 |
Director/Board Member | 8 |
Chief Executive Officer | 3 |
Undergraduate Degree | 3 |
Doctorate Degree | 2 |
Contatti più connessi
Insiders | |
---|---|
Malcolm Weir | 9 |
Barry Kenny | 8 |
Miles Congreve | 5 |
Chris Cargill | 4 |
Ed Hulme | 1 |
Beverly Lybrand | 1 |
Gebhard Schertler | 1 |
Tomohiro Tohyama | 1 |
- Borsa valori
- Insiders
- Tim Tasker
- Connessioni Società